|
시장보고서
상품코드
2075784
황반부종 치료 시장 : 치료법별, 적응증별, 최종 사용자별, 지역별Macular Edema Treatment Market, By Treatment Type, By Indication, By End-User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
황반부종 치료 시장은 2026년에 64억 달러로 추정되며, 2033년까지 103억 달러에 이를 전망입니다. 2026-2033년 CAGR 8.4%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 64억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 8.40% | 시장 규모 예측(2033년) : | 103억 달러 |
세계의 황반부종 치료 시장에는 항-VEGF 요법, 코르티코스테로이드 이식제, 레이저 광응고 요법 및 이와 유사한 치료법 범주가 포함됩니다. 이 치료법들은 당뇨성 황반부종(DME), 망막정맥폐쇄증(RVO) 및 포도막염 관련 황반부종에 적용되며, 병원 및 전문 클리닉에서 사용되고 있습니다. 의료 기관들이 성과, 효율성, 비용 대비 효과를 점점 더 중요시함에 따라, 이러한 부문에서의 도입은 꾸준히 확대되고 있습니다.
시장 역학 :
병원 및 전문 클리닉에서 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 세계 황반부종 치료 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 당뇨병성 황반부종(DME) 및 망막정맥폐쇄증(RVO)에 대한 적용 범위가 확대되면서 이러한 추세가 더욱 가속화되고 있습니다.
예를 들어, 시장에 진출한 각 기업은 당뇨성 황반부종(DME) 치료 사례를 위해 설계된 첨단 솔루션을 도입하고 있습니다. 또한, 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 동안 시장에 진출한 기업들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계 황반부종 치료 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 황반부종 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 판매업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 황반부종 치료 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 황반부종 치료 시장 : 치료 유형별(2026-2033년)
제5장 황반부종 치료 시장 : 적응증별(2026-2033년)
제6장 황반부종 치료 시장 : 최종 사용자별(2026-2033년)
제7장 황반부종 치료 시장 : 지역별(2026-2033년)
제1장 경쟁 구도
제2장 섹션
AJY 26.07.09Macular Edema Treatment Market is estimated to be valued at USD 6.40 billion in 2026 and is expected to reach USD 10.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.40 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.40% | 2033 Value Projection: | USD 10.3 billion |
The global macular edema treatment market includes offerings that span Anti-VEGF Therapy, Corticosteroid Implants, and Laser Photocoagulation, and similar treatment type categories. These are applied across Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), and Uveitis-Associated Macular Edema and adopted by Hospitals, and Specialty Clinics. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from Hospitals, and Specialty Clinics, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global macular edema treatment market. Broader adoption across Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for Diabetic Macular Edema (DME) use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global macular edema treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Regeneron Pharmaceuticals, Novartis AG, Roche Holding AG, Pfizer Inc., Bayer AG, Alimera Sciences Inc., Santen Pharmaceutical Co, Ltd., Boehringer Ingelheim, DongKoo Bio & Pharma Co, Ltd., F. Hoffmann-La Roche Ltd., Versant Ventures, and Bausch Health Companies Inc, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global macular edema treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular edema treatment market.
Detailed Segmentation:
- Global Macular Edema Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
- Anti-VEGF Therapy
- Corticosteroid Implants
- Laser Photocoagulation
- Combination Therapy
- Others
- Global Macular Edema Treatment Market, By Indication (Revenue, USD Bn, 2021 - 2033)
- Diabetic Macular Edema (DME)
- Retinal Vein Occlusion (RVO)
- Uveitis-Associated Macular Edema
- Others
- Global Macular Edema Treatment Market, By End-User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Regeneron Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Roche Holding AG
- Pfizer Inc.
- Bayer AG
- Alimera Sciences Inc.
- Santen Pharmaceutical Co, Ltd.
- Boehringer Ingelheim
- DongKoo Bio & Pharma Co, Ltd.
- F. Hoffmann-La Roche Ltd.
- Versant Ventures
- Bausch Health Companies Inc
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Macular Edema Treatment Market By Treatment Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Anti-VEGF Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Corticosteroid Implants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Laser Photocoagulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Macular Edema Treatment Market By Indication, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Diabetic Macular Edema (DME)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Retinal Vein Occlusion (RVO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Uveitis-Associated Macular Edema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Macular Edema Treatment Market By End User, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Macular Edema Treatment Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc..
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alimera Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Santen Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- DongKoo Bio & Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Versant Ventures
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
